Acquired by Novo Nordisk in January 2022
DRNA - Dicerna Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Lexington,
United States
Type: Equity
DRNA price evolution
DRNA
| (in millions $) | 30 Sep 2021 | 30 Jun 2021 | 31 Mar 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $165.76 | $221.21 | $159.11 | $126.77 |
| Short term investments | $399.75 | $371.75 | $385.77 | $442.82 |
| Net receivables | $6.23 | $3.15 | $31.27 | $34.71 |
| Inventory | ||||
| Total current assets | $589 | $616.49 | $594.5 | $618.7 |
| Long term investments | $86.7 | $122.22 | $5.62 | $5.62 |
| Property, plant & equipment | $94.53 | $97.99 | $77.9 | $78.39 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $183.06 | $222 | $88.91 | $89.14 |
| Total investments | $486.45 | $493.97 | $391.39 | $448.44 |
| Total assets | $772.06 | $838.49 | $683.41 | $707.85 |
| Current liabilities | ||||
| Accounts payable | $8.32 | $12.83 | $11.28 | $7.9 |
| Deferred revenue | $550.55 | $608.61 | $456.27 | $474.77 |
| Short long term debt | $4.89 | $3.95 | $4.07 | $3.44 |
| Total current liabilities | $239.29 | $207.65 | $182.15 | $177.94 |
| Long term debt | $59.52 | $61.2 | $47.57 | $48.74 |
| Total noncurrent liabilities | $425.1 | $519.77 | $374.86 | $392.15 |
| Total debt | $64.42 | $65.15 | $51.64 | $52.18 |
| Total liabilities | $664.4 | $727.42 | $557.01 | $570.09 |
| Shareholders' equity | ||||
| Retained earnings | -$725.91 | -$708.84 | -$668.03 | -$638.06 |
| Other shareholder equity | ||||
| Total shareholder equity | $107.66 | $111.07 | $126.4 | $137.75 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $126.77 | $152.82 | $54.24 | $68.79 |
| Short term investments | $442.82 | $196.06 | $248.39 | $44.89 |
| Net receivables | $34.71 | $200.35 | $100 | $1.58 |
| Inventory | ||||
| Total current assets | $618.7 | $556.17 | $405.51 | $118.56 |
| Long term investments | $5.62 | $3.89 | $0.74 | $0.74 |
| Property, plant & equipment | $78.39 | $37.18 | $2.72 | $1.51 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $89.14 | $41.24 | $3.53 | $2.33 |
| Total investments | $448.44 | $199.96 | $249.13 | $45.63 |
| Total assets | $707.85 | $597.41 | $409.04 | $120.88 |
| Current liabilities | ||||
| Accounts payable | $7.9 | $6.08 | $15.51 | $4.92 |
| Deferred revenue | $474.77 | $394.99 | $183.19 | $9 |
| Short long term debt | $3.44 | $3.36 | ||
| Total current liabilities | $177.94 | $241.74 | $94.06 | $16.65 |
| Long term debt | $48.74 | $20.14 | ||
| Total noncurrent liabilities | $392.15 | $203.48 | $114.29 | $3 |
| Total debt | $52.18 | $23.5 | ||
| Total liabilities | $570.09 | $445.21 | $208.35 | $19.65 |
| Shareholders' equity | ||||
| Retained earnings | -$638.06 | -$525.32 | -$404.81 | -$315.8 |
| Other shareholder equity | ||||
| Total shareholder equity | $137.75 | $152.19 | $200.69 | $101.24 |
| (in millions $) | 30 Sep 2021 | 30 Jun 2021 | 31 Mar 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $62.95 | $41.34 | $47.6 | $40.96 |
| Cost of revenue | ||||
| Gross Profit | $62.95 | $41.34 | $47.6 | $40.96 |
| Operating activities | ||||
| Research & development | $61.23 | $56.12 | $56.04 | $54.02 |
| Selling, general & administrative | $21.99 | $25.46 | $20.67 | $18.58 |
| Total operating expenses | $83.23 | $81.58 | $76.71 | $72.61 |
| Operating income | -$20.27 | -$40.24 | -$29.11 | -$31.65 |
| Income from continuing operations | ||||
| EBIT | -$16.26 | -$40.27 | -$29.96 | -$36.57 |
| Income tax expense | $0.81 | $0.55 | ||
| Interest expense | $0 | $0 | $0 | $0.02 |
| Net income | ||||
| Net income | -$17.07 | -$40.81 | -$29.96 | -$36.59 |
| Income (for common shares) | -$17.07 | -$40.81 | -$29.96 | -$36.59 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $164.31 | $23.9 | $6.18 | $2.28 |
| Cost of revenue | ||||
| Gross Profit | $164.31 | $23.9 | $6.18 | $2.28 |
| Operating activities | ||||
| Research & development | $205.38 | $109.34 | $45.71 | $36.98 |
| Selling, general & administrative | $72.13 | $42.75 | $21.68 | $25.88 |
| Total operating expenses | $277.51 | $152.09 | $96.53 | $62.86 |
| Operating income | -$113.21 | -$128.19 | -$90.35 | -$60.59 |
| Income from continuing operations | ||||
| EBIT | -$112.73 | -$120.46 | -$88.25 | -$60.05 |
| Income tax expense | ||||
| Interest expense | $0.02 | $0 | $0.6 | |
| Net income | ||||
| Net income | -$112.75 | -$120.46 | -$88.85 | -$60.05 |
| Income (for common shares) | -$112.75 | -$120.46 | -$88.85 | -$80.14 |
| (in millions $) | 30 Sep 2021 | 30 Jun 2021 | 31 Mar 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$17.07 | -$40.81 | -$29.96 | -$36.59 |
| Operating activities | ||||
| Depreciation | $4.65 | $4.56 | $3.48 | -$4.93 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $11.23 | $13.63 | $12.41 | $9.6 |
| Total cash flows from operations | -$63.78 | $158.84 | -$26.7 | -$47.3 |
| Investing activities | ||||
| Capital expenditures | -$0.02 | -$4.84 | -$3.38 | -$4.25 |
| Investments | $5.9 | -$103.76 | $56.26 | -$37.73 |
| Total cash flows from investing | $5.88 | -$108.61 | $52.89 | -$41.98 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.59 | $12.34 | $7.58 | $11.03 |
| Net borrowings | ||||
| Total cash flows from financing | $2.45 | $11.87 | $6.16 | $11.02 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$55.45 | $62.1 | $32.34 | -$78.26 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Net income | -$112.75 | -$120.46 | -$88.85 | -$60.05 |
| Operating activities | ||||
| Depreciation | $2.22 | $1.25 | $0.77 | $0.78 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $38.91 | $18.82 | $7.89 | $7.77 |
| Total cash flows from operations | $175.11 | -$0.69 | $18.3 | -$45.33 |
| Investing activities | ||||
| Capital expenditures | -$11.75 | -$6.35 | -$0.36 | -$0.13 |
| Investments | -$247.13 | $55.88 | -$202.37 | -$19.72 |
| Total cash flows from investing | -$258.86 | $49.53 | -$202.73 | -$19.48 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $59.47 | $52.89 | $169.92 | $43.2 |
| Net borrowings | ||||
| Total cash flows from financing | $59.42 | $52.89 | $169.88 | $112.73 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$24.32 | $101.73 | -$14.55 | $47.92 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 77.89M |
| Revenue | $192.85M |
|---|---|
| EBITDA | -$115.29M |
| EBIT | -$123.05M |
| Net Income | -$124.44M |
| Revenue Q/Q | 28.81% |
| Revenue Y/Y | 47.86% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 1.38 |
| Cash/Share | 2.13 |
| EPS | -$1.60 |
|---|---|
| ROA | -16.58% |
| ROE | -103.08% |
| Debt/Equity | 4.14 |
|---|---|
| Net debt/EBITDA | -4.33 |
| Current ratio | 2.46 |
| Quick ratio | 2.46 |